Supplementary Data from Neratinib-Plus-Cetuximab in Quadruple-WT (&lt;i&gt;KRAS, NRAS, BRAF, PIK3CA&lt;/i&gt;) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study